Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is a leading generic drug manufacturer with a strong presence in North America, Europe, Japan, Russia, and Israel. It also has a portfolio of innovative medicines and biosimilars in the neurology and immunology therapeutic areas. The company is executing well against its Pivot to Growth plan, with a potential line of sight to 30% operating margin by 2027. The stock has high visibility into significant expansion in its neuroscience segment, and with continued advancement of its immunology-focused pipeline, we see further multiple expansion and growth opportunities.

Bears say

Teva Pharmaceutical Indus is expected to face stiff competition in the generic drug industry, as other companies enter the market and pricing pressures increase. The acquisition of Emalex adds to Teva's growing debt load, and there is uncertainty surrounding the success of its innovative medicines and biosimilars. Additionally, the slow uptake of Ecopipam and the potential for stronger uptake of Olanzapine LAI over Uzedy may also impact Teva's financial performance.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.